Henry Schein to form strategic partnership with Biotech Dental Group

Henry Schein, Inc. announced an agreement to acquire a majority stake in Biotech Dental Group.

Pending regulatory approvals, the acquisition aims to expand Henry Schein’s offering in several fast-growing product segments including clinical software and oral surgery and orthodontic products, said Henry Schein in a press release.

“Henry Schein and Biotech Dental are committed to offering customers best-in-class, user-friendly, customer-centric solutions based on open architecture that help improve patient outcomes,” said Stanley M. Bergman, Chairman of the Board and CEO of Henry Schein.

End-to-end clinical system

“Henry Schein will, over time, incorporate Biotech’s Nemotec software as part of our solutions offering, including integrating Biotech’s software solutions with Henry Schein One’s industry-leading practice management software solutions to create a leading end-to-end clinical system and to help dental practitioners streamline their clinical as well as administrative workflow.”

According to the press release, Henry Schein hopes to bring Biotech Dental’s full line of high-quality software, products, and services, including dental prostheses, clear aligners, dental implants, regenerative solutions, and biomaterials, to more dentists and dental laboratories as well as new geographies.

“Biotech Dental has excelled in several of the most exciting and fastest-growing segments of the dental market, including implants and aligners,” said Mr Bergman.

“With our combined resources, we will introduce customers to state-of-the-art technology. We are committed to maintaining the French operations of Biotech, which will become centers of excellence for some of our combined processes and manufacturing operations.”

Rooted in French heritage

Biotech Dental’s comprehensive range of solutions include: Nemotec, an integrated suite of planning and diagnostic software that connects disparate devices to create a digital view of the patient’s oral health condition; Smilers® brand of clear aligners; LaGalaxy®, a comprehensive, open, and secure software platform where both clinical and administrative tasks can be performed.

“We have continually grown to meet the specialized and unique needs of dentists, orthodontists, and dental laboratories,” said Philippe Veran, Biotech Dental Founder and President.

“For the past 35 years, the growth of our business has been rooted in our rich French heritage. This will remain as we continue to manufacture our products in France while bringing innovation and new technologies to the global dental community. Together, with Henry Schein, we look forward to helping our customers enhance their surgical skills, achieve better outcomes for their patients, and maximize business success.”

Mr Veran will continue to lead the business, supported by Dr. Olivia Veran, a dental surgeon who is Biotech’s Senior Vice President and Managing Director. Biotech Dental’s revenue was approximately $100 million for the fiscal year 2021.

About Biotech Dental Group

Biotech Dental designs and manufactures a full range of dental implants, implant treatment planning software, orthodontic aligners, regenerative products and digital dentistry solutions.

About Henry Schein, Inc.

Henry Schein, Inc. HSIC is a dental solutions company for health care professionals. With approximately 22,000 Team Schein Members worldwide, the Company’s network of advisors provides more than 1 million customers globally with more than 300 Business, Clinical, Technology, and Supply Chain solutions.

Henry Schein operates through a centralized and automated distribution network, with a selection of more than 120,000 branded products and Henry Schein private-brand products in stock, as well as more than 180,000 additional products available as special-order items. A FORTUNE 500 Company and a member of the S&P 500® index, Henry Schein is headquartered in Melville, N.Y., and has operations or affiliates in 32 countries and territories.